BioStar Capital and Cue Growth co-lead financing to accelerate pivotal trial readiness and expand the ventricular tachycardia (VT) treatment market
Field Medical, a clinical-stage company redefining cardiac ablation with next-generation pulsed field ablation (PFA) technology, announced the close of a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors.
Health Technology Insights: JLL Partners Announces Investment in Vascular Technology, Incorporated
The Series B financing will support the initiation of the company’s pivotal VERITAS trial, advance the FieldForce Ablation System development, and further expand Field Medical’s clinical and regulatory capabilities. The raise was catalyzed in part by strong pilot data presented at the 2025 Heart Rhythm Society meeting. With this round, Field Medical has raised $75 million to date, further solidifying its leadership in PFA innovation for complex arrhythmias.
Health Technology Insights: OneOncology, HOATC Partner to Advance Cancer Care in Florida
“Ventricular tachycardia is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need,” said Steven Mickelsen, MD, founder and CEO of Field Medical. “What is exciting is how VT is mirroring the early days of the AF market, strong clinical demand unmet by existing technology. We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.”
“Field Medical’s transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency,” said Louis Cannon, MD, founder and senior managing director of BioStar Capital. “Their physician-led team brings the right insight, and their FieldForce platform brings the right tools. We’re proud to support this next chapter as they move closer to transforming VT care.”
“This round reflects the momentum building behind Field Medical, not only from our clinical results, but also from the strength of our business fundamentals,” said Oskar Dadason, CFO of Field Medical. “Our strong showing at HRS attracted institutional investor interest and reinforced continued support from existing investors, speaking volumes about the confidence in our technology, strategy, and leadership.”
Health Technology Insights: Virta Health Appoints Laura Walmsley as Chief Commercial Officer
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
